Pharmacokinetics of Fentanyl Buccal Tablet: A Pooled Analysis and Review

Pain Practice

Volumn 12, Issue 4, 2012, Pages 307-314

  Darwish, Mona ^a   Xie, Fang ^a  

^a CEPHALON INC   (United States)

Author keywords

Breakthrough pain; Chronic pain; Fentanyl; Fentanyl buccal tablet; Opioid analgesics; Opioid tolerant; Pain; Pharmacokinetics; Rapid onset opioids

Indexed keywords

FENTANYL; NALTREXONE;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 84859444109     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00491.x     Document Type: Review

References (38)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-281.
2. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
3. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55-64.
4. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.
5. Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage. 1998;16:179-183.
6. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7:583-591.
7. Stanley TH. Fentanyl. J Pain Symptom Manage. 2005;29(suppl 5):S67-S71.
8. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv. 2006;4:1-5.
9. FENTORA [package insert]. Frazer, PA: Cephalon, Inc.; January 2011.
10. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327-334.
11. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-811.
12. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer. 2009;115:2571-2579.
13. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:588-601.
14. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin. 2007;23:223-233.
15. Farrar JT, Messina J, Xie F, Portenoy RK. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med. 2010;11:1313-1327.
16. Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manage. 2010;40:747-760.
17. Pather SI, Siebert JM, Hontz J, Khankari R, Kumbale R, Gupte S. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system. Drug Deliv Technol. 2001;1:54-57.
18. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol. 2007;47:343-350.
19. Darwish M, Tempero K, Kirby M, Thompson J. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1, 080μg versus oral transmucosal fentanyl citrate 1, 600μg and dose proportionality of FEBT 270 to 1, 300μg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther. 2006;28:715-724.
20. Hug CC Jr, Murphy MR. Tissue redistribution of fentanyl and termination of its effects in rats. Anesthesiology. 1981;55:369-375.
21. Hudson RJ, Thomson IR, Cannon JE, Friesen RM, Meatherall RC. Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. Anesthesiology. 1986;64:334-338.
22. Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44:1279-1286.
23. Darwish M, Kirby M, Robertson P Jr, Hellriegel E, Jiang JG. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet. 2006;45:843-850.
24. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800μg in healthy adult volunteers. Clin Ther. 2006;28:707-714.
25. Darwish M, Kirby M, Robertson P Jr, Hellriegel E, Jiang JG. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J Clin Pharmacol. 2007;47:56-63.
26. Darwish M, Kirby M, Jiang JG, Tracewell W, Robertson P Jr. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400μg in healthy subjects. Clin Drug Investig. 2008;28:1-7.
27. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Xie F. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300μg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study. Clin Drug Investig. 2010;30:365-373.
28. Ashburn M, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011;112:693-702.
29. Saunders DL, Messina J, Darwish M, Xie F, Leary KJ, Cantilena LR. Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain model. J Clin Pharmacol. 2011. [Epub ahead of print].
30. FDA Web site. Guidance for Industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Draft guidance. Available at: (accessed July 17, 2011).
31. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100-800μg in healthy volunteers. Int J Clin Pharmacol Ther. 2010;48:860-867.
32. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at: (accessed July 19, 2011).
33. Darwish M, Kirby M, Jiang JG. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin Pharmacother. 2007;8:2011-2016.
34. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177-1191.
35. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877-2885.
36. Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308-1314.
37. Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617-624.
38. Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008;30:469-481.